Genome editing-based therapies become the predominant technology of the 21st century with promising statements about genetic diseases treatments. Genome editing tools recently emerged but they suffer from an absence of standardization and their applications remain limited. In this context, Quidditas developed a novel genome editing platform which permits an absolute genetic recombination. Compatible with a larger scope of applications, from bioprocess improvement to genetic disorders treatment, this revolutionary technique will have a major impact in the synthetic Bio field. So “Let’s cure from the beginning!”
| Website | https://www.quidditastherapeutics.com/ |
| Employees | 7 (3 on RocketReach) |
| Founded | 2022 |
| Industry | Biotechnology Research |
| Keywords | Gene Editing Tools, Genome Editing, Novel Therapies, Gene Therapy, Genetic Diseases, Targeted Therapies, Crispr Technology, Biotechnology, Life Sciences, Therapeutics, Pharmaceutical, Drug Discovery, Clinical Trials, Genetic Engineering, Rare Diseases, Precision Medicine, Molecular Biology, Rna Therapy, Cell Therapy |
Looking for a particular QUIDDITAS employee's phone or email?
François Cherbonneau is the CEO and Co-founder of QUIDDITAS.
3 people are employed at QUIDDITAS.
QUIDDITAS is based in Liège, Walloon Region.